Clinical trials: Vasovagal Syncope (VVS), active
Vasovagal Syndrome VVS, Cardioinhibitory Carotid Sinus Syndrome CSS
POLish Registry of CArdioneuroablation and CArdioneuromodulation
The multicentre observational study POL-CA involves a wide spectrum of patients with a history of syncopy. The study recruits patients with diagnosed vasovagal syndrome, cardioinhibitory carotid sinus syndrome, symptomatic sinus…
- Conditions
- Vasovagal Syndrome VVS, Cardioinhibitory Carotid Sinus Syndrome CSS, Symptomatic Sinus Bradycardia SB or Atrioventricular Block AV, Postural Orthostatic Tachycardia Syndrome POTS
- Trial name
- POL-CA (NCT07196397)
- Testing
- cardioneuroablation, SN sparing hybrid ablation, Cardiac sympathetic denervation
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- SABAMED Medical Center Ltd.
Vasovagal Syncope (VVS), Presyncope
A Warning Red Flag Classification System to Predict Risk of Vasovagal Event During Office Hysteroscopy
The goal of this pilot cross sectional study is to identify participants at risk of vasovagal reaction/syncope(VVR/VVS) during office hysteroscopy.
- Trial name
- FLAG-VS (NCT07030218)
- Testing
- Office hysteroscopy
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tanvir Hospital
Vasovagal Syncope (VVS)
Assesment of the Clinical Benefit of Provocation on Tilt-table in SYNCope Patients, TiltSYNC-trial
multicenter prospective randomized controlled comparison of biofeedback with tilt table testing (investigational management strategy) vs biofeedback without tilt table testing (reference management strategy) in patients with…
- Trial name
- TiltSYNC (NCT07459478)
- Testing
- biofeedback and standard of care with tilt table testing, no tilt table testing
- Where
- Netherlands
- Volunteers
- 238 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Vasovagal Syncope (VVS), Syncope
A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11)
About 20% of adults faint recurrently. These patients are often highly symptomatic, have problems with employment and driving, can be injured, and have poor quality of life.
- Trial name
- POST 11 (NCT05755737)
- Testing
- Ondansetron
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Calgary